Jan 29 (Reuters) - Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a muscle wasting disorder, than its older drug Exondys 51. (Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.1 USD | -1.31% | -2.67% | +33.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.90% | 12.2B | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-3.99% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
-28.60% | 7.83B | |
+17.28% | 8.01B |
- Stock Market
- Equities
- SRPT Stock
- News Sarepta Therapeutics, Inc.
- Sarepta says its experimental Duchenne drug more effective than older medicine